Raytheon awarded $71 million in Navy contracts for missile systems
CAMBRIDGE, MA—Bethany J. Cavanagh, Senior Vice President of Finance and Treasurer at Beam Therapeutics Inc . (NASDAQ:BEAM), recently sold 3,015 shares of the company’s common stock. The transaction, which took place on April 1, 2025, was valued at approximately $55,330, with shares sold at a weighted average price of $18.35. The sale comes amid a challenging year for the $1.34 billion market cap company, which has seen its stock decline about 34% year-to-date. According to InvestingPro analysis, BEAM is currently trading below its Fair Value, with a financial health rating of "Fair."
The sale was conducted as a non-discretionary transaction to cover tax withholding obligations related to the vesting of restricted stock units. These sales were executed under a Rule 10b5-1 trading plan adopted by Cavanagh on August 9, 2024. Following this transaction, Cavanagh retains ownership of 44,512 shares in Beam Therapeutics. For comprehensive insider trading analysis and additional financial metrics, InvestingPro subscribers can access detailed reports covering 1,400+ US stocks, including BEAM’s complete insider transaction history.
In other recent news, Beam Therapeutics has announced significant developments surrounding its BEAM-302 treatment for Alpha-1 Antitrypsin Deficiency (AATD). The company received approval from the FDA for its investigational new drug application for BEAM-302, marking a critical step forward in addressing this genetic disorder. Beam Therapeutics also shared positive trial data, showing dose-dependent increases in total serum Alpha-1 Antitrypsin levels, which surpassed the protective therapeutic threshold. No serious adverse events were reported, highlighting a favorable safety profile for the treatment.
Analyst actions have reflected confidence in Beam Therapeutics’ progress. BofA Securities upgraded the company’s stock rating to Buy, citing the promising data on BEAM-302 and setting a price target of $42. Meanwhile, Citi raised its price target to $64, maintaining a Buy rating, driven by the positive trial outcomes and the company’s successful $500 million follow-on offering. Bernstein SocGen Group maintained its Outperform rating and a $37 price target, noting the clean safety profile and encouraging trial results.
These developments underscore Beam Therapeutics’ commitment to advancing its pipeline and leveraging its proprietary lipid nanoparticle technology. The company’s efforts continue to attract positive attention from analysts, with expectations of further advancements in its gene editing therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.